Objective To explore the relationship between insulin resistance (IR) and benign prostatic hyperplasia (BPH) in elderly men of different ages.Methods Totally 100 elderly outpatients with BPH in our hospital from January 2012 to June 2012 were recruited in this study.All patients were divided into 2 groups according to age:60-75 years(n =52) and 76-93 years (n=48).Fasting plasma glucose,fasting insulin (FINS) and prostate specific antigen (PSA) were assayed.Insulin resistance index (IRI) was calculated by using the homeostasis model assessment-insulin resistance (HOMA2-IR) software.The body height,body weight,waist circumference were measured and the body mass index (BMI) was calculated.Prostate volume (PV) was measured by abdominal ultrasound.Clinical data were compared between the two groups.Based on HOMA2-IR,patients were divided into insulin resistant group (IR＞ 1.7) and non insulin resistant group (IR＜ 1.7).Serum PSA,PV and waist circumference were compared between the two groups.Results The waist circumference and PV were significantly larger in insulin resistant group than in non-insulin resistant group [(96.6± 7.2) cm vs.(93.1±8.9) cm,(50.0±9.0) ml vs.(46.1±7.8) ml,respectively,P＜0.01,0.05].However,the PSA level was lower in insulin resistant group than in non-insulin resistant group [(1.44±1.08) μg/L vs.(2.1 ±2.0)μg/L,P＜0.05],and no correlation was found between HOMA-IR and PV.There was no correlation between serum PSA levels and PV in patients aged 76-93 years.In patients aged 60-75 years,PSA level was positively correlated with PV (r =0.52,P＜0.05) and negatively correlated with HOMA-IR (r=0.38,P＜0.05).Conclusions Serum PSA level is positively correlated with PV and negatively correlated with HOMA IR in BPH patients under 75 years old.

Objective To establish a mathematical model of early PMI and RNA △Cq under different causes of death,which provides a reference for early PMI inference under the condition of changing causes of death.Methods Thirty adult male SD rats with SPF level were randomly divided into 5 groups with 6 animals in each group(Death by carotid artery major hemorrhage;Death by strangle;Death by drown;Death by organophosphorus pesticides;Death by CO poisoning).The rats were placed in a constant temperature and humidity incubator at 20℃and 55%humidity after death.RNA was extracted from brain tissue at 7 time points within 0～24 h postmortem.The Cq values of five RNA(β-actin,GAPDH,miR-9,miR-124,miR-125b)were measured at each time point.QBase+V(3.4)software geNorm program was used to select the internal parameters.The correlation between early PMI and RNA △Cq was analyzed by SAS 9.4 software,and a mathematical model was established.Another 15 adult male SD rats with SPF level were randomly divided into 5 groups.The RNA from brain tissue were collected at 10 h and 20 h after death for back-inference verification.Results(1)The fluorescence of miR-124 could not be captured in this experimental system,and this gene could not be used as a candidate gene in this experimental system.(2)The stability of the four genes(β-actin,GAPDH,miR-9 and miR-125b)in rat brain tissue varied under different conditions of death.Using SAS 9.4 software,the correlation analysis were conducted between early postmortem interval(PMI)and RNA △Cq values,and the mathematical models were set up for early PMI estimation.Conclusion(1)The causes of death can affect the degradation of RNA in postmortem brain tissue of rats,and different reference genes should be selected under different causes of death.(2)The mathematical model established under this experimental system can provide reference for early postmortem PMI inference of different causes of death.

Surgery is the preferred treatment for resectable esophageal cancer, but in locally advanced esophageal cancer, the effect of surgery alone is not ideal, so surgery-based comprehensive treatment is the best option. Neoadjuvant therapy has become a standard treatment in the treatment of locally advanced resectable esophageal cancer. Neoadjuvant therapy includes neoadjuvant chemotherapy, radiochemotherapy, immunotherapy, targeted therapy, etc. With the significant efficacy and acceptable toxicity of immunotherapy in the first-line and second-line treatment of advanced esophageal cancer, neoadjuvant immunotherapy has become a research hotspot of locally advanced resectable esophageal cancer. This article reviews the latest research progress and some limitations of neoadjuvant immunotherapy in locally advanced resectable esophageal cancer.